<?xml version='1.0' encoding='utf-8'?>
<document id="23116892"><sentence text="Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction."><entity charOffset="30-55" id="DDI-PubMed.23116892.s1.e0" text="3-methoxy-2-aminopyridine" /></sentence><sentence text="(S)-1-((4-(3-(6-Amino-5-methoxypyridin-3-yl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-ol, 1, was recently identified as a potent inhibitor of the oncogenic kinase bRAF"><entity charOffset="0-105" id="DDI-PubMed.23116892.s2.e0" text="(S)-1-((4-(3-(6-Amino-5-methoxypyridin-3-yl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-ol" /></sentence><sentence text=" Compounds containing 3-methoxy-2-aminopyridine, as in 1, comprised a promising lead series because of their high ligand efficiency and excellent ADME profile"><entity charOffset="22-47" id="DDI-PubMed.23116892.s3.e0" text="3-methoxy-2-aminopyridine" /></sentence><sentence text=" However, following metabolic oxidation, compounds in this series also demonstrated two significant safety risks: mutagenic potential and time-dependent drug-drug interaction (TDI)" /><sentence text=" Metabolite identification studies revealed formation of a reactive metabolite" /><sentence text=" We hypothesized that minimizing or blocking the formation of such a metabolite would mitigate the safety liabilities" /><sentence text=" Our investigation demonstrated that structural modifications which either reduced the electron density of the 3-methoxy-2-aminopyridine ring or blocked the reactive site following metabolic oxidation were successful in reducing TDI and AMES mutagenicity"><entity charOffset="111-136" id="DDI-PubMed.23116892.s7.e0" text="3-methoxy-2-aminopyridine" /></sentence><sentence text="" /></document>